Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies
Immunogenic cell death (ICD) is a promising cancer therapy where dying tumor cells release damage-associated molecular patterns (DAMPs) to activate immune responses. Recent research highlights the critical role of metabolic reprogramming in tumor cells, including the Warburg effect, oxidative stress...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/4/950 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850156154309574656 |
|---|---|
| author | Jie Jiang Yan Yan Chunhui Yang Hong Cai |
| author_facet | Jie Jiang Yan Yan Chunhui Yang Hong Cai |
| author_sort | Jie Jiang |
| collection | DOAJ |
| description | Immunogenic cell death (ICD) is a promising cancer therapy where dying tumor cells release damage-associated molecular patterns (DAMPs) to activate immune responses. Recent research highlights the critical role of metabolic reprogramming in tumor cells, including the Warburg effect, oxidative stress, and lipid metabolism, in modulating ICD and shaping the immune microenvironment. These metabolic changes enhance immune activation, making tumors more susceptible to immune surveillance. This review explores the molecular mechanisms linking ICD and metabolism, including mitochondrial oxidative stress, endoplasmic reticulum (ER) stress, and ferroptosis. It also discusses innovative therapeutic strategies, such as personalized combination therapies, metabolic inhibitors, and targeted delivery systems, to improve ICD efficacy. The future of cancer immunotherapy lies in integrating metabolic reprogramming and immune activation to overcome tumor immune evasion, with multi-omics approaches and microbiome modulation offering new avenues for enhanced treatment outcomes. |
| format | Article |
| id | doaj-art-8fdf4a8210b240469708246777477df3 |
| institution | OA Journals |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-8fdf4a8210b240469708246777477df32025-08-20T02:24:39ZengMDPI AGBiomedicines2227-90592025-04-0113495010.3390/biomedicines13040950Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic StrategiesJie Jiang0Yan Yan1Chunhui Yang2Hong Cai3Department of Clinical Laboratory, The Second Hospital of Dalian Medical University, Dalian 116023, ChinaDepartment of Clinical Laboratory, The Second Hospital of Dalian Medical University, Dalian 116023, ChinaDepartment of Clinical Laboratory, The Second Hospital of Dalian Medical University, Dalian 116023, ChinaDepartment of Clinical Laboratory, The Second Hospital of Dalian Medical University, Dalian 116023, ChinaImmunogenic cell death (ICD) is a promising cancer therapy where dying tumor cells release damage-associated molecular patterns (DAMPs) to activate immune responses. Recent research highlights the critical role of metabolic reprogramming in tumor cells, including the Warburg effect, oxidative stress, and lipid metabolism, in modulating ICD and shaping the immune microenvironment. These metabolic changes enhance immune activation, making tumors more susceptible to immune surveillance. This review explores the molecular mechanisms linking ICD and metabolism, including mitochondrial oxidative stress, endoplasmic reticulum (ER) stress, and ferroptosis. It also discusses innovative therapeutic strategies, such as personalized combination therapies, metabolic inhibitors, and targeted delivery systems, to improve ICD efficacy. The future of cancer immunotherapy lies in integrating metabolic reprogramming and immune activation to overcome tumor immune evasion, with multi-omics approaches and microbiome modulation offering new avenues for enhanced treatment outcomes.https://www.mdpi.com/2227-9059/13/4/950immunogenic cell deathmetabolic reprogrammingtumor microenvironmentcancer immunotherapy |
| spellingShingle | Jie Jiang Yan Yan Chunhui Yang Hong Cai Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies Biomedicines immunogenic cell death metabolic reprogramming tumor microenvironment cancer immunotherapy |
| title | Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies |
| title_full | Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies |
| title_fullStr | Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies |
| title_full_unstemmed | Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies |
| title_short | Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies |
| title_sort | immunogenic cell death and metabolic reprogramming in cancer mechanisms synergies and innovative therapeutic strategies |
| topic | immunogenic cell death metabolic reprogramming tumor microenvironment cancer immunotherapy |
| url | https://www.mdpi.com/2227-9059/13/4/950 |
| work_keys_str_mv | AT jiejiang immunogeniccelldeathandmetabolicreprogrammingincancermechanismssynergiesandinnovativetherapeuticstrategies AT yanyan immunogeniccelldeathandmetabolicreprogrammingincancermechanismssynergiesandinnovativetherapeuticstrategies AT chunhuiyang immunogeniccelldeathandmetabolicreprogrammingincancermechanismssynergiesandinnovativetherapeuticstrategies AT hongcai immunogeniccelldeathandmetabolicreprogrammingincancermechanismssynergiesandinnovativetherapeuticstrategies |